Incyte saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 78 to 82.
IBD's unique RS Rating tracks technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the last 52 weeks matches up against other publicly traded companies.
Over 100 years of market history reveals that the market's biggest winners often have an RS Rating of over 80 as they launch their biggest runs.
Hone Your Stock-Picking Skills By Focusing On These Factors
Incyte is working on a consolidation with an 83.95 buy point. See if it can clear the breakout price in heavy volume.
Earnings growth picked up last quarter from -3% to 35%. But revenue gains fell from 24% to 16%.
Incyte holds the No. 37 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Exelixis and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
